DUARTE, Calif.--(BUSINESS WIRE)--Aug 15, 2019-- The first-in-human, phase 1 T cell trial for patients who have human papillomavirus (HPV)-associated cancers that have relapsed, or are resistant to treatment, is now open at City of Hope. The institution is the first to open such a trial on the West Coast. The research trial, which is sponsored by Kite, a Gilead Company, targets HPV-associated cancers with the HPV type 16, a strain which causes about 70% of all cervical cancers worldwide, as well as oropharyngeal, anal, penile and vaginal cancers. Nearly 88,000 HPV-associated cancers will be diagnosed this year in the United States, and the American Cancer Society estimates that more than...
|